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Abstract
Myeloperoxidase (MPO)-derived oxidants have emerged as a key contributor to tissue
damage in inflammatory conditions such as cardiovascular disease. Pro-myeloperoxidase
(pro-MPO), an enzymatically active precursor of myeloperoxidase (MPO), is known to be
secreted from cultured bone marrow and promyelocytic leukemia cells, but evidence for the
presence of pro-MPO in circulation is lacking. In the present study, we used a LC-MS/MS in
addition to immunoblot analyses to show that pro-MPO is present in human blood plasma.
Furthermore, we found that pro-MPO was more frequently detected in plasma from patients
with myocardial infarction compared to plasma from control donors. Our study suggests that
in addition to mature MPO, circulating pro-MPO may cause oxidative modifications of pro-
teins thereby contributing to cardiovascular disease.
Introduction
The heme peroxidase myeloperoxidase (MPO), a neutrophil-resident bactericidal enzyme,
uses hydrogen peroxide to oxidize chloride and thiocyanate to hypochlorous and hypothiocya-
nous acids, respectively [1, 2]. Bromide is a minor substrate and is oxidized to hypobromous
acid [3]. While MPO-derived oxidants play a key role in the innate immune-response by facili-
tating microbial killing, they have also emerged as a contributor to progressive tissue damage
during chronic inflammation, i.e. in cardiovascular disease [4]. Monomeric pro-myeloperoxi-
dase (pro-MPO) is a catalytically active precursor of MPO [5, 6], but whether it is present in
human plasma and whether it contributes to cardiovascular disease is unknown.
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The biosynthesis MPO involves a complex series of proteolytic processing and trafficking
events. Initially, a single primary 80 kDa translation product is expressed in promyelocytes in
human bone marrow [7]. Subsequent cleavage of the signal peptide and incorporation of heme
and high mannose oligosaccharide then yields the enzymatically active 90 kDa monomeric
pro-MPO [8, 9]. After cleavage of the pro-peptide, proteolytic processing produces a 14.5 kDa
light and a 59 kDa heavy chain, both of which are covalently bound to the heme. Furthermore,
disulfide bond formation between two heavy chains produces mature MPO—a symmetric 147
kDa homodimer [6], which is targeted to azurophilic granules. Mature MPO is released from
those granules into the phagosome of stimulated neutrophils [10].
MPO-catalyzed reactions are thought to be involved in all stages of cardiovascular disease,
from the initial development of endothelial dysfunction through to the advancement of a mature
atherosclerotic plaque and finally its rupture (reviewed in [11]). MPO-derived oxidants can pro-
mote lipid peroxidation [12, 13] as well as induce oxidative modifications in proteins including
halogenation, nitration and oxidative cross-linking [14, 15]. The presence of 3-chlorotyrosine resi-
dues for example has been demonstrated in LDL present in atherosclerotic plaques [16].
Pro-MPO has similar spectroscopic and enzymatic properties as mature MPO, but a lower
thermal stability [5, 6, 9]. A recently solved crystal structure of pro-MPO suggests a role for the
pro-peptide in aiding proper folding and heme insertion of the enzyme in the endoplasmic
reticulum (ER) [6]. It also facilitates transport from the ER to the Golgi apparatus for subse-
quent proteolytic cleavage [6]. Interestingly, not all of the pro-MPO that is synthesised com-
pletes the maturation process to the more thermally stable dimeric MPO. Pro-MPO has been
shown to escape proteolytic processing and targeting to the azurophilic granules and to be
constitutively secreted by cultured normal bone marrow granulocyte precursors [7] and
human promyelocytic leukemia cells (HL-60) [7, 17, 18]. In 1986, Olsen et al. also demon-
strated the presence of a precursor form in plasma using immunoprecipitation and immuno-
blot analysis [19]. The apparent molecular weight of the immune-reactive precursor was
consistent with pro-MPO, but the sequence of the polypeptide was not identified.
We hypothesized that in addition to circulating MPO, catalytically active pro-MPO can
contribute to oxidative modifications of proteins leading to cardiovascular disease. The pres-
ence of pro-MPO in patients with cardiovascular disease has not been investigated.
The aim of this study was to confirm the presence of pro-MPO in plasma using LC-MS/MS
in addition to immunoblot analyses. Furthermore, we investigated whether pro-MPO was ele-
vated in patients with myocardial infarction (MI).
Experimental
Materials
Purified human myeloperoxidase was supplied by Planta Natural Products (Vienna, Austria).
Heterologous expression, purification of recombinant monomeric pro-MPO in CHO cells,
and characterization have been described [20, 21]. The concentration of MPO and pro-MPO
was determined by measuring its absorbance at 430 nm and using ε430 = 89000 M
-1cm-1/
heme, and its purity index was calculated by A430/A280 [22]. NHS-activated Sepharose 4 Fast
Flow was purchased from GE Healthcare Life Sciences (Uppsala, Sweden). Rabbit anti-MPO
polyclonal antibodies were produced in-house. Antibody production in rabbits was approved
by the University of Otago Animal Ethics Committee (# C05/05). One New Zealand white rab-
bit (5 months old, sourced from Rapid Rabbits) was immunized with human MPO (7.5 μM)
injected subcutaneously with Freund’s complete adjuvant (St Louis, MO, USA) at three sites
(250 μl/site) at the back of the neck down the spine. Two boosters were injected at 30 day inter-
vals with Freund’s incomplete adjuvant. Test bleeds were from the marginal ear artery and the
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monitoring.
final bleed via cardiac puncture. The rabbit was given acepromazine for the test bleeds, ice
packs were applied and the animal monitored afterwards. Cardiac puncture was carried out
under ketamine and xylazine after testing for any response, then cervical dislocation was per-
formed to confirm death. Animals were socialised, handled daily and monitored by staff with
daily reports.
All other chemicals were purchased from Sigma (St Louis, MO, USA), BDH (Poole, UK)
and Biolab Thermo Fisher Chemicals (Adelaide, Australia).
Halogenation activity of mature MPO and recombinant pro-MPO
The reaction of MPO-generated hypobromous or hypochlorous acid with NADH was moni-
tored by measuring the formation of the bromohydrin or chlorohydrin product at 275 nm
[23]. Initial rates of NADH oxidation were determined with increasing concentrations of bro-
mide (0–20 mM) or chloride (0–300 mM), 20 nM MPO and 100 μM NADH in 50 mM phos-
phate buffer (pH 7.4) at 21˚C. NADH solutions were prepared in 50 mM phosphate buffer, pH
7.4 and concentrations confirmed by absorbance readings at 340 nm using ε340 = 6220 M
–1
cm–1.The reaction was started by adding 50 μM H2O2. Extinction coefficient for the bromohy-
drin and chlorohydrin products of ε275 = 92000 M
–1 cm–1 and ε275 = 11000 M
–1 cm–1 were
used, respectively [24]. A non-linear hyperbola was fitted to the data using SigmaStat 11 soft-
ware (Jandel Scientific, San Rafael, CA, USA).
Plasma samples and isolation of human neutrophils
Blood was collected from healthy human volunteers with written informed consent, and with
ethical approval from the Southern Health & Disability Ethics Committee, New Zealand, into
tubes containing either EDTA or heparin for obtaining plasma or neutrophils, respectively.
EDTA-treated blood was centrifuged at 1200 g for 10 min at 4˚C and plasma was separated
and stored at -80˚C until further processing. Human neutrophils were isolated from heparin-
ized blood by dextran sedimentation followed by Ficoll/Hypaque centrifugation and erythro-
cyte lysis in hypotonic buffer [25]. Plasma samples from patients with myocardial infarction
(MI) were obtained as part of studies described elsewhere and were stored at -80˚C [26]. All
participants gave written, informed consent.
HL-60 cells
HL-60 cells were cultured and lysed as described previously with the following modifications
[27]. Cells were grown to a density of 1x106 cells/m and harvested by centrifuging 50 ml at
1000 g for 5 min. Cells were re-suspended in buffer A (6.7 mM sodium phosphate buffer pH
6.0, 1 mM MgCl2, 3 mM NaCl and protease inhibitors) at a ratio of 10 ml buffer A to 1 ml cell
pellet. CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate) was added
to a final concentration of 1% and rotated for 2 h at 4˚C. The supernatant was obtained by cen-
trifugation at 20000 g for 20 min at 4˚C.
Immunoprecipitation of MPO from plasma and immunoblot analysis
Rabbit polyclonal anti-human MPO antibodies were produced in-house and precipitated from
antiserum by adding saturated ammonium sulphate solution (final concentration of 50%) at
4˚C, the pellet was re-suspended in water and dialyzed into PBS. Purified human MPO was
covalently coupled to NHS-Sepharose 4 Fast Flow beads following manufacturer’s instructions
(0.125 mg of MPO/ml medium). Four ml of the above immunoglobulin fraction was loaded
onto 2 ml of MPO-Sepharose and incubated by mixing on rotator overnight at 4˚C. The
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medium was centrifuged at 200 g for 2 min, washed with PBS, eluted with 0.9 ml of 0.1 M gly-
cine, pH 3.0 and the pH was neutralized with 0.1 ml 1M Tris-HCl, pH 8.0. Eluted fractions
with an absorbance at 280 nm of 0.03 to 0.5 were combined and buffer-exchanged into PBS
using AMICON filters with a 10 kDa molecular weight cut off (Millipore, Billerica, MA).
Immobilisation of the purified anti-MPO antibodies on NHS-activated Sepharose 4 Fast Flow
beads (about 1 mg of anti-MPO to 2 ml of medium) was performed as above, and used for iso-
lation of immune-reactive MPO from plasma. One ml of plasma diluted in PBS (1:2) was
added to 400 μl of washed anti-MPO-Sepharose medium and incubated on a rotator overnight
at 4˚C. The medium was washed with PBS and MPO was eluted three times by adding 575 μl
of 0.1 M glycine, pH 3.0 and neutralized with 25 μl 1 M Tris-HCl, pH 8.0. Eluates were com-
bined and proteins were precipitated by adding 20% [v/v] trichloroacetic acid/ 20% [v/v] ace-
tone/ 0.1% [w/v] sodium deoxycholate. Air-dried precipitates were re-suspended in reducing
SDS-PAGE loading buffer (4% [w/v] SDS, 10% [v/v] glycerol, 125 mM Tris-HCl buffer pH 6.5,
0.1% [v/v] β-mercaptoethanol), heated at 95˚C for 5 min and then separated by 10% SDS-
PAGE. Proteins were transferred to PVDF membranes and incubated with rabbit anti-MPO
antiserum produced in-house followed by goat anti-rabbit IgG conjugated to horseradish per-
oxidase for visualization by the ECL detection system.
Tryptic digestion and LC-MS analysis
MPO standards or air-dried precipitates obtained after affinity-chromatography purification
of plasma samples were solubilized in 100 μl of 6 M guanidine hydrochloride (GuHCl) in 25
mM bicarbonate buffer, pH 8.0 and 5 μl of 200 mM diothiothreitol was added and incubated
at 57˚C for 1 h. Twenty-five μl of 200 mM IAM was added and incubated in the dark for
30 min at 22˚C. GuHCl was diluted to 0.6 M with 25 mM bicarbonate buffer and trypsin
(sequencing grade, Promega Corporation, Madison, WI) was added at a ratio of approximately
1/20 (trypsin/protein) and incubated at 37˚C overnight. Samples were dried and adjusted to a
volume of 60 μl with water containing 0.1% formic acid. Fifty μl of sample was loaded onto an
Aries Peptide XB C-18 HPLC column (150 x 2.1 mm, 3.6 μm, Phenomenex, Torrance, CA) for
HPLC-MS analysis using a Surveyor HPLC system (Thermo Scientific, San Jose, CA). An ace-
tonitrile gradient from 98% solvent A (0.1% formic acid in water) to 100% solvent B (0.1% for-
mic acid in acetonitrile) was run over 25 min at a flow rate of 200 μl/min. After each gradient,
solvent B was held at 100% for 5 min followed by column equilibration over 10 min with 98%
solvent A. The HPLC was coupled inline to an electrospray ionization source of a Velos Pro
mass spectrometer (Thermo Scientific, Waltham, MA). Voltage was 4 kVolts and nitrogen gas
flow was 15 AU. The temperature of the heated capillary was 275˚C and vaporizer temperature
was 400˚C. MRM data were acquired in positive mode between 3.5 and 30 min of each chro-
matographic run for a pro-MPO and MPO-specific peptides as well as a peptide present in
both proteins. The pro-MPO-specific peptide SSGcAYQDVGVTcPEQDK (c, carbamido-
methyl-cysteine) and MPO-specific peptide VTcPEQDKYRwere detected using the MS1/MS2
transition pairs 1000.9 /1033.5 and 648.8 / 935.5, respectively and the peptide present in both
proteins RNGFPVALAR using 551.8 / 272.2 (MS1 = m/z for the doubly charged precursor spe-
cies and MS2 = m/z for the singly charged y ion fragment). Additionally, full CID-MS/MS
spectra were acquired from m/z 200 to 2000 for the precursors (MS1). The window for precur-
sor selection was 1 Da on either side of the m/z; the normalized collision energy was 35 and
activation time 30 msec. The longer mature MPO-specific tryptic peptide, VTCPEQDKYRwas
chosen for SRM analysis over the shorter VTCPEQDK peptide as the latter was not detected.
In some cases, immunoprecipitates were separated by 10% SDS/PAGE under non-reducing
conditions as described above. After staining with Coomassie Blue, the 90 kDa band expected
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to contain pro-MPO was excised from the SDS/PAGE gel and subjected to in-gel digestion
with trypsin at a ratio of 1/20 w/w at 37˚C overnight. Tryptic fragments were eluted from the
gel matrix using 80% acetonitrile, 0.1% FA, dried and taken up in 60 μl water containing 0.1%
FA and analyzed by LC-MS/MS as described above.
Results
Production of hypobromous and hypochlorous acid by pro-MPO
compared to mature MPO
Others have shown that pro-MPO oxidizes chloride and bromide at similar rates to the mature
enzyme [5]. We wanted to confirm these results and show that hypohalous acids are produced
by pro-MPO. To achieve this, we determined the rate of oxidation of NADH by the MPO/
H2O2/halide system, which is known to produce halohydrins [23]. Recombinant monomeric
pro-MPO showed very similar bromination activity as mature MPO as demonstrated by simi-
lar rates for the hypobromous acid-dependent oxidation of NADH (Fig 1). The chlorination
activity of pro-MPO was about 70% of that of mature MPO.
Detection of pro-MPO in plasma using affinity purification and
immunoblot analysis
To isolate MPO from human plasma, we purified MPO-specific antibodies from rabbit antise-
rum produced in-house and immobilized the antibodies on Sepharose. First, we tested
Fig 1. Halogenation activity of mature MPO and recombinant pro-MPO. Initial rates of NADH oxidation were determined with various concentrations of A)
bromide or B) chloride, 20 nM mature MPO or recombinant pro-MPO and 100 μM NADH in 50 mM phosphate buffer (pH 7.4) at 21˚C. The reaction was started by
adding 50 μM H2O2. The kinetics of the reaction of myeloperoxidase-generated hypobromous and hypochlorous acids with NADH were monitored by measuring the
bromohydrin and chlorohydrin product at 275 nm. Data are representative of two or more experiments.
https://doi.org/10.1371/journal.pone.0192952.g001
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whether anti-MPO-Sepharose could isolate pro-MPO and mature MPO from control plasma
spiked with purified human mature MPO and HL-60 cell lysate containing both mature and
pro-MPO [7] (Fig 2A). Spiked mature and pro-MPO were successfully recovered from plasma
using anti-MPO-Sepharose. Interestingly, a protein with the electrophoretic mobility of
Fig 2. Detection of mature MPO and pro-MPO in plasma using affinity-purification and immunblot analysis. A)
Plasma was spiked with MPO standard (10 nM) and HL60 cell lysate (containing 10 nM MPO) and subjected to
affinity purification. Purified samples along with MPO, pro-MPO standards and HL-60 lysates were separated by 10%
SDS/PAGE, transferred to PVDF and probed with MPO-specific antibody. B) Neutrophils (5x106 cells/ml) were added
back into plasma and then stimulated with CytB and FMLP for 30 min at 37˚C. Neutrophils were centrifuged and cell
free plasma MPO was subjected to affinity purification and analyzed as described in A. After the ECL fluorescence of
blots was developed, a photograph of the blot showing the molecular weight markers was taken and aligned with the
fluorescence image as indicated by the black line.
https://doi.org/10.1371/journal.pone.0192952.g002
Pro-myeloperoxidase in circulation
PLOS ONE | https://doi.org/10.1371/journal.pone.0192952 March 28, 2018 6 / 15
mature MPO was also isolated from unspiked plasma, but none with the molecular weight of
pro-MPO.
Next, we tested whether neutrophils release pro-MPO when added back into control
plasma and stimulated with FMLP. While we observed an increase in the intensity of the
mature MPO band, pro-MPO was not released into plasma by stimulated neutrophils (Fig 2B).
We then used anti-MPO-Sepharose to purify immune-reactive MPO from plasma from
patients with myocardial infarction and from healthy controls (Fig 3). Bands consistent with
the molecular weight of both mature MPO and pro-MPO were detected in plasma from con-
trols and patients. Both bands were more intense in plasma from patients compared to con-
trols (Fig 3). We affinity-purified ten samples in each of the control and myocardial infarction
and subsequent immunblot analysis showed both bands to be consistently elevated in the clini-
cal samples. Some healthy volunteers donated control plasma for affinity purification and
immunblot analysis on more than one occasion. The intensity of the pro-MPO and mature
MPO relative to each other varied suggesting a different physiological source or turn-over for
the two proteins.
Detection of pro-MPO in plasma using affinity purification and LC-MS
analysis
To confirm that the 90 kDa band observed in immunoblots corresponds to pro-MPO and that
it is elevated in patient samples, we developed an LC-MS/MS method for the detection of a
tryptic peptide specific for pro-MPO, mature MPO as well as a peptide present in both species.
Fig 3. Detection of mature MPO and pro-MPO in plasma from healthy controls and patients with myocardial
infarction using affinity-purification and immunblot analysis. Plasma from control subjects and from patients with
myocardial infarct (MI) was subjected to affinity purification and analyzed by immunoblot as described Fig 1. This
blot is representative of at least 10 plasma samples in each group. After the ECL fluorescence of blots was developed, a
photograph of the blot showing the molecular weight markers was taken and aligned with the fluorescence image as
indicated by the black line.
https://doi.org/10.1371/journal.pone.0192952.g003
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The peptide amino acid sequences of the chosen peptides and their location within the MPO
sequence is shown in Fig 4A. All three peptides were separated by C-18 chromatography (Fig
4B, 4D and 4F) and collision induced (CID)-MS/MS spectra confirmed the amino acid
sequence of each peptide (Fig 4C, 4E and 4G). From these spectra, SRM transitions specific for
each peptide were chosen for subsequent SRM analyses of in-gel and in-solution tryptic digests
of plasma samples purified by affinity chromatography. The signal intensity for the mutual
peptide was 10-fold higher compared to the pro-MPO or mature MPO specific peptides.
Using the SRM-based LC-MS/MS method, we investigated the recovery of the pro-MPO-,
mature MPO-specific and the mutual peptide after affinity purification and tryptic digestion
of plasma spiked either 90% MPO and 10% pro-MPO or 10% MPO and 90% pro-MPO
(Table 1). The LC-MS signal for the pro-MPO- and mature MPO- specific peptides reflected
the spiked protein ratios and the signal for the mutual peptide was similar in the two prepara-
tions. These results indicate that the MPO-specific antibodies used for affinity purification
have a similar affinity to both mature MPO and pro-MPO.
Next, we wanted to confirm by in-gel tryptic digestion that the protein migrating at the
molecular weight of pro-MPO (90 kDa) observed in immunoblots of affinity-purified plasma
samples contained the pro-MPO-specific peptide. However, protein staining of the corre-
sponding SDS/PAGE gel with coomassie did not show a 90 kDa band indicating that the
amount of protein present in the gel was below the limit of detection of our mass spectrometer.
Due to limited sample availability, we were unable to scale up the affinity-purification of clini-
cal plasma samples. In contrast, control plasma samples were obtained fresh for the purpose of
this study, and we were able to increase the amount of control plasma used for affinity-purifi-
cation by 25-fold. We obtained a corresponding 90 kDa coomassie-stained band and in-gel
tryptic digestion showed it to contain the pro-MPO specific tryptic peptide (Fig 5).
To circumvent likely losses of protein associated with SDS/PAGE and in-gel tryptic diges-
tion, we also performed in-solution digests of immunoprecipitates (Fig 6A–6D). Using this
method, the pro-MPO-specific was detected in 25% of plasma samples from patients with
myocardial infarction (n = 3/12), but only in 11% of samples from control subjects (n = 1/9).
The MPO-specific peptide was detected in 42% of myocardial infarction samples (n = 5/12)
and 22% of control samples (n = 2/9) (Table 2).
Discussion
In the present study we show by MPO affinity-purification of plasma with subsequent immu-
noblot and LC-MS/MS analyses that pro-MPO, an enzymatically active precursor of MPO is
present in circulation. Our data further shows that circulating pro-MPO, like MPO, is elevated
in patients with cardiovascular disease.
Prior to this work, only one study has suggested the presence of pro-MPO in circulation
when a 90 kDa band was observed in immunoblot analysis of affinity-purified plasma [19].
Therefore, the physiological and pathological role of the precursor form of MPO, pro-MPO,
remains largely unexplored. Mature MPO, in contrast, has been extensively studied with
regard to its role in host defence and inflammatory conditions [4]. In this study, we confirm
that pro-MPO is present plasma and elevated in cardiovascular disease patients using a combi-
nation of immunoblot analysis and LC-MS/MS.
Here we show that pro-MPO has bromination and chlorination activity similar to that of
the mature enzyme. A kinetic study previously compared pro-MPO and mature MPO purified
from human blood using multi-mixing stopped flow technique, in which the redox intermedi-
ates of these two enzymes were found to be indistinguishable [5]. A recent crystal structure
confirms that the active site structure remains conserved during the maturation process from
Pro-myeloperoxidase in circulation
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pro-MPO to mature MPO [6]. Pro-MPO, like MPO, therefore has the ability to oxidize chlo-
ride to hypochlorous acid, an activity that is unique among the mammalian heme peroxidases
[28]. We hypothesise that circulating pro-MPO can contribute to oxidative cell damage such
as that previously attributed to mature MPO in cardiovascular disease [11].
The source of circulating pro-MPO is elusive and needs further study. Our data suggests
that the release of pro-MPO into plasma is independent of neutrophil activation and degranu-
lation as activated neutrophils did not release pro-MPO into plasma. Also, immunoblots of
plasma obtained from the same person on different occasions showed that the ratio of pro-
MPO to mature MPO is not constant indicating alternative mechanisms for the release of
these two enzymes into circulation. MPO is only actively synthesized by promyelocytes and
promyelomonocytes during the differentiation process of granulocytes in the bone marrow
when azurophilic granules are formed [29, 30]. It has previously been demonstrated in a neu-
trophil precursor cell line (HL-60) that pro-MPO is secreted into the cell culture medium, but
was absent in the granules [7, 17, 18]. Therefore, it seems likely that pro-MPO in plasma origi-
nates directly from immature granulocytes in the bone marrow.
Plasma and serum levels of mature MPO correlate well with the total number of neutrophils
in the blood indicating that circulating neutrophils are the main source for mature MPO [31,
32]. However, serum MPO has also been suggested to stem directly from the bone marrow
during periods of increased myelopoietic activity such as in childhood or during pregnancy
[32]. If pro-MPO, unlike MPO, originates exclusively from myelocyte precursors in the bone
marrow, then plasma levels of pro-MPO could be explored as marker of increased or ineffec-
tive bone marrow activity.
Here, we demonstrate that pro-MPO is elevated in patients with myocardial infarction indi-
cating its prognostic potential that warrants further study. Pro-MPO in plasma from the car-
diovascular patients might also stem from tissue macrophages, the prominent cell type in
atherosclerotic lesions, where MPO has been shown to be expressed [33]. Under normal con-
ditions macrophages only express little MPO. It is possible that MPO gene transcription has
been activated in foam cell macrophages due to the presence of cytokines in the environment
of the atherosclerotic plaque. For example, agonists of peroxisome proliferator-activated recep-
tor (PPAR) have shown to regulate MPO gene expression [34–36] and PPAR is abundant in
Fig 4. LC-MS/MS analysis of mutual, pro-MPO- and MPO- specific peptides. A) Location of tryptic peptides used
for LC-MS/MS analysis within the MPO sequence. The N-terminal signal peptide is shown in dark grey, the pro-
peptide in bold light grey and the sequence of mature MPO in bold black. Highlighted by the black and grey boxes are
tryptic peptides specific to pro-MPO or present in both mature MPO and pro-MPO, respectively. Twenty-five μg of
recombinant pro-MPO or mature MPO were digested with trypsin and analyzed by LC-MS/MS. B), D) +F) Extracted
ion chromatograms for SRM transitions specific for the mutual, pro-MPO and mature MPO-specific peptides (MS1/
MS2 551.8/272.2, 1000.9/1033.5 and 648.8/935.5, respectively, MS1 = m/z for the doubly charged precursor species and
MS2 = m/z for the singly charged y–ion fragment, c–carbamidomethyl-cysteine). C), E) +G) CID-MS/MS spectra
confirming the sequence of the respective peptide. Representative chromatograms and spectra are shown.
https://doi.org/10.1371/journal.pone.0192952.g004
Table 1. Recovery of the pro-MPO-, MPO-specific and mutual peptide after affinity purification, tryptic digestion and detection by LC-MS/MS. Plasma was spiked
with one μg of total MPO containing either 90% MPO and 10% pro-MPO or vice versa, subjected to affinity purification with MPO-specific antibodies, digested with tryp-
sin and analyzed by SRM-based LC-MS/MS. The area under the curve (AUC) for the pro-MPO-specific peptide, mature MPO-specific peptide and the mutual peptide are
shown (see Fig 4). Data are presented as means ± range of two independent experiments.
% Pro-MPO /
% mature MPO
AUC of peptide specific for
Mature MPO
x 102
Pro-MPO
x 102
Both
x 104
10 / 90 0.73 ± 0.12 0.34 ± 0.05 4.29 ± 0.17
90 / 10 0.19 ± 0.04 3.40 ± 0.26 3.91 ± 0.16
https://doi.org/10.1371/journal.pone.0192952.t001
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foam cell macrophages [37]. Foam cells undergoing de novo MPO synthesis due to the act-
ivation by local cytokines could lack the cellular machinery to process pro-MPO to mature
MPO. This would result in constitutive secretion of pro-MPO into circulation and explain
why in the present study pro-MPO was more readily detected in patients with cardiovascular
conditions.
Finally, we need to acknowledge the limitations of our study. The clinical samples used for
the present work were used for earlier studies and had been stored at -80˚C for up to five years
and freeze-thawed two to three times prior to this work. Therefore, proteins may already have
undergone some degradation. Furthermore, the sensitivity of the ion trap mass analyser used
for this study is low and the amount of plasma used for the affinity purification could not be
increased due to limited sample availability. Collectively, this may explain the very low signal
intensity when analysing immunoprecipitates by SRM-based LC-MS/MS and the fact that
only a small number of y-ions were detected when full CID-MS/MS spectra were collected.
Pro-MPO was detected in a greater percentage of patient samples by immunoblot analysis
than by LC-MS/MS indicating the superior sensitivity of the immunochemical method. Con-
sequently, our present data does not allow for any quantitative comparisons between control
and disease groups due to the low sensitivity of the LC-MS/MS method, the small number and
quality of the patient plasma samples. However, we consider the present study a proof-of con-
cept study that warrants recruiting a greater number of samples using a more sensitive mass
spectrometer like a contemporary triple-quad.
Fig 5. LC-MS/MS detection of pro-MPO in affinity-purified plasma separated by SDS/PAGE. Plasma was purified by affinity chromatography with an MPO-specific
antibody and subjected to separation by SDS/PAGE. Bands with the molecular weight of pro-MPO (90 kDa) were subjected to in-gel tryptic digestion and analyzed by
LC-MS/MS using SRM for a pro-MPO-specific peptide (1000.9->1033.5). (A) Extracted ion chromatogram for the SRM transition for the pro-MPO specific peptide.
(B) CID-MS/MS spectrum confirming the sequence for the pro-MPO-specific peptide SSGcAYQDVGVTcPEQDK. Representative chromatograms and spectra are
shown.
https://doi.org/10.1371/journal.pone.0192952.g005
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Conclusions
Our study shows that a precursor of MPO, pro-MPO, is present in circulation and elevated in
patients with cardiovascular disease. Since enzymatically active, pro-MPO can catalyse the oxi-
dation of proteins and lipoproteins thereby fuelling the progression of an atherosclerotic lesion
independent of neutrophil activation and the release of mature MPO from the azurophilic
granules. Furthermore, circulating pro-MPO has the potential to be used as a marker of
Fig 6. LC-MS/MS detection of pro-MPO and mature MPO in affinity-purified plasma from patients with myocardial infarction (MI). Plasma was purified by
affinity chromatography with an MPO-specific antibody, subjected to digestion with trypsin and analyzed by LC-MS/MS. A) Representative SRM- based extracted ion
chromatogram for the pro-MPO specific peptide (1000.9->1033.5) and C) the mature MPO-specific peptide (648.8->935.5) measured in a MI plasma sample. B)+D)
CID-MS/MS spectra were recorded simultaneously for m/z 1000.9 and 648.8 representing the SSGcAYQDVGVTcPEQDK and VTcPEQDKYR peptides, respectively.
https://doi.org/10.1371/journal.pone.0192952.g006
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increased bone marrow activity. We hope that these results will stimulate further studies into
the role of this enzyme plays in circulation.
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